Vanda Pharmaceuticals (VNDA) Goodwill & Intangibles (2010 - 2026)

Vanda Pharmaceuticals has disclosed Goodwill & Intangibles across 17 years of filings, most recently posting $115.1 million for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $115.1 million, up 2.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (up 2.45% YoY), and the FY2025 annual result was $117.1 million, up 2.62% from the prior year.
• Goodwill & Intangibles came in at $115.1 million for Q1 2026 at Vanda Pharmaceuticals, down from $117.1 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $121.4 million in Q4 2023 to a low of $17.4 million in Q3 2023.
• The 5-year median for Goodwill & Intangibles is $110.6 million (2025), against an average of $75.4 million.
• Across the five-year window, Goodwill & Intangibles dropped 8.0% in 2023 and surged 564.72% in 2024, its largest moves.
• Vanda Pharmaceuticals' Goodwill & Intangibles stood at $18.6 million in 2022, then soared by 553.75% to $121.4 million in 2023, then declined by 5.99% to $114.1 million in 2024, then rose by 2.62% to $117.1 million in 2025, then slipped by 1.7% to $115.1 million in 2026.
• The last three Goodwill & Intangibles figures came in at $115.1 million (Q1 2026), $117.1 million (Q4 2025), and $108.8 million (Q3 2025), per Business Quant data.